This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05446/identifier/chemspider/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05446/identifier/pubchem-compound/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB05446/identifier/drugbank/

Statements

Subject Item
n2:DB05446
rdf:type
n3:Drug
n3:description
LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1. LJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. Antibody-mediated thrombosis, also called antiphospholipid syndrome (APS), is a blood clotting disorder. Patients with high levels of anticardiolipin antibodies (ACA) have an increased risk of stroke, heart attack, deep vein thrombosis, and recurrent fetal loss. The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. To date, our scientists have shown that approximately 90% of patients studied with antibody-mediated thrombosis have antibodies that bind to this region.
n3:generalReferences
# Cockerill KA, Iverson GM, Jones DS, Linnik MD: Therapeutic potential of toleragens in the management of antiphospholipid syndrome. BioDrugs. 2004;18(5):297-305. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15377172 # Merrill JT: LJP 1082: a toleragen for Hughes syndrome. Lupus. 2004;13(5):335-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15230288 # Bayes M, Rabasseda X, Prous JR: Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Dec;25(10):831-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14735233
n3:group
investigational
n3:indication
Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.
owl:sameAs
n6:DB05446
dcterms:title
LJP 1082
adms:identifier
n8:DB05446 n9:1082 n11:1052
n3:mechanismOfAction
The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I.
n3:IUPAC-Name
n4:271B43E0-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B43E6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B43E5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B43E2-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B43E3-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B43E4-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B43DE-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B43DF-363D-11E5-9242-09173F13E4C5 n4:271B43DC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B43DD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B43EC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B43ED-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B43E7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B43E8-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B43EA-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B43E9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B43EB-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B43F2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B43F4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B43F5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B43F1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B43F0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B43F3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B43E1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B43EE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B43EF-363D-11E5-9242-09173F13E4C5